Full Press Release Details
Creative Medical Technology
Holdings, Inc. April 2019 Shareholder Update
April 30, 2019 /PRNewswire/ -- (OTCQB-CELZ) Creative Medical Technology Holdings, Inc. announced today an update of its activities:
are releasing updates on a regular basis, we will only cover new activities. The absence of reporting on a specific area of our
business should not be construed as a lack of concentration in that area but due to the short window of time between shareholder
updates. We appreciate our shareholders' desire for "real time" information but some aspects of our business take time.
domestic activities: We are continuing marketing to physicians across the United States. Since our last shareholder update an additional
five physicians have expressed interest in joining CaverStem(TM). We are currently vetting those physicians and will submit contracts
for their review and signature. Once contracts are in place, we will schedule training and begin marketing for patient awareness.
physicians came to us through our physician marketing program. We are continuing to use this marketing tool with mailers and emails
with follow up telephone communication with physicians across the country.
disclosed, we have and will continue to use social media to build patient awareness with the use of Google Ad Words and banner
advertising. We believe social media is a great resource as 80% of patients find us, using their phones and tablets. In order to
continue to grow patient awareness print advertising is now being used and we are continuing to develop our television commercial
which will be edited to direct patients to each physician in their area.
and his staff at North Florida Urology were trained on April 24(th) with five patients successfully treated. Training for Dr. Liu
in San Francisco is scheduled on May 2(nd) and Dr. Sanderson in Honolulu will be trained in May. Other physicians are scheduled
testimonials discussing the procedure and the positive results are being filmed and will be posted on our caverstem.com website
and our social media pages.
International activities: We are continuing to treat patients in Italy and the first patients treated within the past 2 months
have expressed positive results. This will be covered in a separate press release by Dr. Antonini and the company.
our electronic patient registry is complete and is being forwarded to physicians. This registry is intended to include data from
our clinical trial, data from treating physicians using centrifuge technology with a 30cc to 60cc bone marrow aspiration and our
second generation, needle only, mini bone marrow aspiration technology drawing a maximum of 20cc of bone marrow. Recent publications
have disclosed that with the second generation needle technology a larger amount of pure cell product is harvested because of a
reduction in dilution of blood, thus requiring a reduced bone marrow aspiration. The registry will enable the company to gather
and maintain ongoing HIPAA compliant information on patient demographics, history and treatment progress. Patient names and addresses
will not be included on the registry or disclosed to the company.
received positive feedback from treating physicians in the United States and Europe of a 70% to 100% efficacy in their patients.
This percentage may fluctuate depending on the age and health of the patients and cause and severity of their erectile dysfunction.
as previously announced, we are progressing with the development of the FemCelz(TM) procedure for the treatment of female sexual
dysfunction. The first patients are scheduled for May 2(nd) in San Francisco. Additional patients are being scheduled in other
to move forward on all aspects of our business. The dedication of our team towards building the fundamentals of the company and
shareholder value remain as strong as ever and the addition of medical industry veterans allows us to grow the company on a domestic
and international level at a faster pace than at any time since inception of the company.
also like to thank our shareholders for their support, including the many shareholders from the medical field who have expressed
positive feedback on our progress.
currently finalizing our Q1 financials and expect to file by the May 15, 2019 deadline.
Creative Medical Technology Holdings
Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTCQB under the ticker symbol
CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on our Caverstem(TM)
procedure please go to www.caverstem.com.
has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain
forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and
laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore,
involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission
and available on the Commission's website at www.sec.gov.
Creative Medical Technology Holdings, Inc.
Timothy Warbington, Chief Executive Officer, Tel: (480) 789-9939